Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press70610.17650/2313-805X-2024-11-3-32-40REVIEW ARTICLESОБЗОРНЫЕ СТАТЬИMolecular genetic and biochemical profiles of malignant neoplasms during pregnancyМолекулярно-генетический и биохимический профили злокачественных новообразований на фоне беременностиhttps://orcid.org/0000-0002-8194-2811ChernyshovaA. L.ЧернышоваА. Л.
Russian Federation

Elena Leonidovna Chernyshova

15 Rechkunovskaya St., Novosibirsk 630055

52 Krasnyy Prospekt, Novosibirsk 630091

Алена Леонидовна Чернышова

630055 Новосибирск, ул. Речкуновская, 15

630091 Новосибирск, Красный пр-кт, 52

lacher@list.ruhttps://orcid.org/0000-0003-0829-0340ChernyakovA. A.ЧерняковА. А.
Russian Federation

5 Kooperativnyy Pereulok, Tomsk 634009

634009 Томск, пер. Кооперативный, 5

https://orcid.org/0000-0001-5926-2601TruschukYu. M.ТрущукЮ. М.
Russian Federation

5 Kooperativnyy Pereulok, Tomsk 634009

634009 Томск, пер. Кооперативный, 5

https://orcid.org/0000-0003-4595-4177YunusovaN. V.ЮнусоваН. В.
Russian Federation

5 Kooperativnyy Pereulok, Tomsk 634009

2 Moskovskiy Trakt, Tomsk 634050

634009 Томск, пер. Кооперативный, 5

634050 Томск, Московский  тракт, 2

https://orcid.org/0009-0005-0529-5631SevostyanovaN. V.СевостьяноваН. В.
Russian Federation

2 Moskovskiy Trakt, Tomsk 634050

634050 Томск, Московский тракт, 2

https://orcid.org/0009-0002-1062-7344ArkhipovaYa. I.АрхиповаЯ. И.
Russian Federation

2 Moskovskiy Trakt, Tomsk 634050

634050 Томск, Московский тракт, 2

https://orcid.org/0000-0001-6562-7574DilO. S.ДильО. С.
Russian Federation

15 Rechkunovskaya St., Novosibirsk 630055

630055 Новосибирск, ул. Речкуновская, 15

ChernyshovaA. E.ЧернышоваА. Е.
Russian Federation

7/9 Universitetskaya Emb., Saint Petersburg 199034

199034 Санкт-Петербург, Университетская наб., 7/9

E.N. Meshalkin National Medical Center, Ministry of Health of RussiaФГБУ «Национальный медицинский центр им. акад. Е.Н. Мешалкина» Минздрава РоссииNovosibirsk State Medical University, Ministry of Health of RussiaФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава РоссииScientific Research Institute of Oncology, Tomsk National Medical Research Center, Russian Academy of SciencesНаучно-исследовательский институт онкологии ФГНУ «Томский национальный медицинский исследовательский центр Российской академии наук»Scientific Research Institute of Oncology, Tomsk National Medical Research Center, Russian Academy of SciencesНаучно-исследовательский институт онкологии ФГНУ «Томский национальный медицинский исследовательский центр Российской академии наук»Siberian State Medical University, Ministry of Health of RussiaФГБУ ВО «Сибирский государственный медицинский университет» Минздрава РоссииSaint-Petersburg State UniversityФГБОУ ВО «Санкт-Петербургский государственный университет»1509202411332401010202410102024Copyright ©; 2024, Chernyshova A.L., Chernyakov A.A., Truschuk Y.M., Yunusova N.V., Sevostyanova N.V., Arkhipova Y.I., Dil O.S., Chernyshova A.E.Copyright ©; 2024, Чернышова А.Л., Черняков А.А., Трущук Ю.М., Юнусова Н.В., Севостьянова Н.В., Архипова Я.И., Диль О.С., Чернышова А.Е.2024Chernyshova A.L., Chernyakov A.A., Truschuk Y.M., Yunusova N.V., Sevostyanova N.V., Arkhipova Y.I., Dil O.S., Chernyshova A.E.Чернышова А.Л., Черняков А.А., Трущук Ю.М., Юнусова Н.В., Севостьянова Н.В., Архипова Я.И., Диль О.С., Чернышова А.Е.https://creativecommons.org/licenses/by/4.0https://umo.abvpress.ru/jour/article/view/706

The article presents a review of modern literature data on molecular-genetic and biochemical profiles of malignant tumors of varying locations. It is shown that molecular-genetic and transcription profiles of pregnancy-associated malignant tumors are systems consisting of various components, many of which remain poorly researched. Additionally, morphological and biochemical characteristics of the placenta and tumor tissue are discussed. In the recent years, individual researchers and research groups have demonstrated heightened interests in this problem which undoubtedly soon will lead to a deeper and stronger understanding of mechanisms of progression and metastasis of oncological diseases during pregnancy. The knowledge of the principles of normal embryogenesis as a process of intrauterine development of a fetus, as well as investigation of molecular basis of pathogenesis of spontaneous abortion will undoubtedly help in determination of new targets and development of new therapeutical molecules for cancer treatment.

В статье представлен обзор современных данных литературы о молекулярно-генетических и биохимических профилях злокачественных новообразований различных локализаций. Показано, что молекулярно-генетический и транскрипционный профили злокачественных опухолей, ассоциированных с беременностью, являются системами, включающими различные компоненты, многие из которых к настоящему моменту остаются малоизученными. Также рассмотрены морфологические и биохимические особенности плаценты и опухолевой ткани. В последние годы наблюдается повышенный интерес отдельных исследователей и групп ученых к данному вопросу, что, несомненно, в скором времени приведет к более глубокому и четкому пониманию механизмов метастазирования и прогрессирования онкологических заболеваний на фоне беременности. Знание закономерностей нормального эмбриогенеза как процесса внутриутробного развития зародыша в полости матки во время беременности, а также изучение молекулярных основ патогенеза состояний спонтанного прерывания беременности, без сомнения, будут способствовать выявлению новых мишеней и созданию биотерапевтических молекул для лечения рака.

cancerpregnancyplacentamolecular genetic factorbiochemical markerprognosissракбеременностьплацентамолекулярно-генетический факторбиохимический маркерпрогнозLouwen F., Muschol-Steinmetz C., Reinhard J. et al. A lesson for cancer research: placental microarray gene analysis in preeclampsia. Oncotarget 2012;3(8):759–73. DOI: 10.18632/oncotarget.595Costanzo V., Bardelli A., Siena S., Abrignani S. Exploring the links between cancer and placenta development. Open Biol 2018;8(6):180081. DOI: 10.1098/rsob.180081Novakovic B., Saffery R. Placental pseudo-malignancy from a DNA methylation perspective: unanswered questions and future directions. Front Genet 2013;4:285. DOI: 10.3389/fgene.2013.00285Dvorak H.F. Tumors: wounds that do not heal-redux. Cancer Immunol Res 2015; 3(1):1–11. DOI: 10.1158/2326-6066.CIR-14-0209Nancy P., Siewiera J., Rizzuto G. et al. H3K27me3 dynamics dictate evolving uterine states in pregnancy and parturition. J Clin Investig 2018;128(1):233–47. DOI: 10.1172/JCI95937Daassi D., Mahoney K.M., Freeman G.J. The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol 2020;20(4):209–15. DOI: 10.1038/s41577-019-0264-yKornepati A.V.R., Vadlamudi R.K., Curiel T.J. Programmed death ligand 1 signals in cancer cells. Nat Rev Cancer 2022;22(3):174–89. DOI: 10.1038/s41568-021-00431-4Ge Z., Wu S., Zhang Z., Ding S. Mechanism of tumor cells escaping from immune surveillance of NK cells. Immunopharmacol Immunotoxicol 2020;42(3):187–98. DOI: 10.1080/08923973.2020.1742733López-Soto A., Gonzalez S., Smyth M.J., Galluzzi L. Control of metastasis by NK cells. Cancer Cell 2017;32(2):135–54. DOI: 10.1016/j.ccell.2017.06.009Mohme M., Riethdorf S., Pantel K. Circulating and disseminated tumour cells – mechanisms of immune surveillance and escape. Nat Rev Clin Oncol 2017;14(3):155–67. DOI: 10.1038/nrclinonc.2016.144Ferreira L.M.R., Meissner T.B., Tilburgs T., Strominger J.L. HLA-G: at the interface of maternal-fetal tolerance. Trends Immunol 2017;384:272–86. DOI: 10.1016/j.it.2017.01.009Hackmon R., Pinnaduwage L., Zhang J. et al. Definitive class I human leukocyte antigen expression in gestational placentation: HLA-F, HLA-E, HLA-C, and HLA-G in extravillous trophoblast invasion on placentation, pregnancy, and parturition. Am J Reprod Immunol 2017;77(6). DOI: 10.1111/aji.12643Yang F., Zheng Q., Jin L. Dynamic function and composition changes of immune cells during normal and pathological pregnancy at the maternal-fetal interface. Front Immunol 2019;10:2317. DOI: 10.3389/fimmu.2019.02317Gregori S., Amodio G., Quattrone F., Panina-Bordignon P. HLA-G orchestrates the early interaction of human trophoblasts with the maternal niche. Front Immunol 2015;6:128. DOI: 10.3389/fimmu.2015.00128Xu L., Li Y., Sang Y. et al. Crosstalk between trophoblasts and decidual immune cells: the cornerstone of maternal-fetal immunotolerance. Front Immunol 2021;12:642392. DOI: 10.3389/fimmu.2021.642392Soares M.J., Varberg K.M., Iqbal K. Hemochorial placentation: development, function, and adaptations. Biol Reprod 2018;99(1):196–211. DOI: 10.1093/biolre/ioy049Wagner G.P., Kshitiz, Dighe A., Levchenko A. The coevolution of placentation and cancer. Annu Rev Anim Biosci 2022;10:259–79. DOI: 10.1146/annurev-animal-020420-031544Duff D., Long A. Roles for RACK1 in cancer cell migration and invasion. Cell Signal 2017;35:250–5. DOI: 10.1016/j.cellsig.2017.03.005Chen J., Khalil R.A. Matrix metalloproteinases in normal pregnancy and preeclampsia. Prog Mol Biol Transl Sci 2017;148:87–165. DOI: 10.1016/bs.pmbts.2017.04.001Fabijanovic D., Serman L. Epigenetic control of cell invasion – the trophoblast model. Biomol Concepts 2012;3(6):487–94. DOI: 10.1515/bmc-2012-0019Kreis N.N., Friemel A., Ritter A. et al. Function of p21 (Cip1/Waf1/CDKN1A) in migration and invasion of cancer and trophoblastic cells. Cancers 2019;11(7):989. DOI: 10.3390/cancers11070989Xu Y., Sui L., Qiu B. et al. ANXA4 promotes trophoblast invasion via the PI3K/Akt/eNOS pathway in preeclampsia. Am J Physiol Cell Physiol 2019;316(4):481–91. DOI: 10.1152/ajpcell.00404.2018Lv S., Wang N., Lv H. et al. The attenuation of trophoblast invasion caused by the downregulation of EZH2 is involved in the pathogenesis of human recurrent miscarriage. Mol Ther Nucleic Acids 2019;14:377–87. DOI: 10.1016/j.omtn.2018.12.011Xie D., Zhu J., Liu Q. et al. Dysregulation of HDAC9 represses trophoblast cell migration and invasion through TIMP3 activation in preeclampsia. Am J Hypertens 2019;32(5):515–23. DOI: 10.1093/ajh/hpz006Raghu D., Mobley R.J., Shendy N.A.M. et al. GALNT3 maintains the epithelial state in trophoblast stem cells. Cell Rep 2019;26(13):3684–97.e7. DOI: 10.1016/j.celrep.2019.02.093Zhang L., Wang K., Wu Q. et al. Let-7 inhibits the migration and invasion of extravillous trophoblast cell via targeting MDM4. Mol Cell Probes 2019;45:48–56. DOI: 10.1016/j.mcp.2019.05.002Xue F., Yang J., Li Q., Zhou H. Down-regulation of microRNA- 34a-5p promotes trophoblast cell migration and invasion via targetting Smad4. Biosci Rep 2019;39(2):BSR20181631. DOI: 10.1042/BSR20181631Piechowski J. Plausibility of trophoblastic-like regulation of cancer tissue. Cancer Manag Res 2019;11:5033–46. DOI: 10.2147/CMAR.S190932Knofler M., Haider S., Saleh L. et al. Human placenta and trophoblast development: Key molecular mechanisms and model systems. Cell Mol Life Sci 2019;76(18):3479–96. DOI: 10.1007/s00018-019-03104-6Davies J.E., Pollheimer J., Yong H.E. et al. Epithelial-mesenchymal transition during extravillous trophoblast differentiation. Cell Adhes Migr 2016;10(3):310–21. DOI: 10.1080/19336918.2016.1170258Gamage T., Schierding W., Hurley D. et al. The role of DNA methylation in human trophoblast differentiation. Epigenetics 2018;13(12):1154–73. DOI: 10.1080/15592294.2018.1549462Pollheimer J., Vondra S., Baltayeva J. et al. Regulation of placental extravillous trophoblasts by the maternal uterine environment. Front Immunol 2018;9:2597. DOI: 10.3389/fimmu.2018.02597Novakovic B., Stunnenberg H.G. I Remember you: epigenetic priming in epithelial stem cells. Immunity 2017;47(6):1019–21. DOI: 10.1016/j.immuni.2017.12.005Chen Q., Tong M., Guo F. et al. Parity correlates with the timing of developing endometrial cancer, but not subtype of endometrial cancer. J Cancer 2015;6(11):1087–92. DOI: 10.7150/jca.12736Adami H.O., Hsieh C.C., Lambe M. et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994;344(8932):1250–4. DOI: 10.1016/s0140-6736(94)90749-8Wentzensen N., Poole E.M., Trabert B. et al. Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. J Clin Oncol 2016;34(24):2888–98. DOI: 10.1200/JCO.2016.66.8178Troisi R., Bjørge T., Gissler M. et al. The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence. J Intern Med 2018;283(5):430–45. DOI: 10.1111/joim.12747Main C., Chen X., Zhao M. et al. Understanding how pregnancy protects against ovarian and endometrial cancer development: fetal antigens may be involved. Endocrinology 2022;163(11):bqac141. DOI: 10.1210/endocr/bqac141Torres D., Hou X., Bale L. et al. Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A. PLoS One 2019;14(11):e0224564. DOI: 10.1371/journal.pone.0224564Conover C.A., Oxvig C. PAPP-A and cancer. J Mol Endocrinol 2018; 61(1):T1–10. DOI: 10.1530/JME-17-0236Yunusova N.V., Kondakova I.V., Kolomiets L.A. et al. Molecular targets for the therapy of cancer associated with metabolic syndrome (transcription and growth factors). Asia-Pac J Clin Oncol 2018;14(3):134–40. DOI: 10.1111/ajco.12780Kolomiets L.A., Chernysheva A.L., Sukhodolo I.V., Kritskaya N.G. Prognostic criteria of oncologic risk in endometrial proliferative processes. Sibirskiy onkologicheskiy zhurnal = Siberian Oncologic Journal 2007;S1. (In Russ.).Коломиец Л.А., Чернышева А.Л., Суходоло И.В., Крицкая Н.Г. Критерии прогноза онкологического риска при пролиферативных процессах эндометрия. Сибирский онкологический журнал 2007;S1.Oncogynecology: national guidelines. Eds.: A.D. Kaplin, L.A. Ashrafyan, I.S. Stilidi. Moscow: GEOTAR-Media, 2019. 384 p. (In Russ.).Онкогинекология: национальное руководство. Под ред. А.Д. Каприна, Л.А. Ашрафяна, И.С. Стилиди. М.: ГЭОТАР-Медиа, 2019. 384 с.Khare P., Bose A., Singh P. et al. Gonadotropin and tumorigenesis: direct and indirect effects on inflammatory and immunosuppressive mediators and invasion. Mol Carcinog 2017;56(2):359–70. DOI: 10.1002/mc.22499Lempiäinen A., Stenman U.H., Blomqvist C., Hotakainen K. Free beta-subunit of human chorionic gonadotropin in serum is a diagnostically sensitive marker of seminomatous testicular cancer. Clin Chem 2008;54(11):1840–3. DOI: 10.1373/clinchem.2008.108548Jankowska A.G., Andrusiewicz M., Fischer N., Warchol P.J. Expression of hCG and GnRHs and their receptors in endometrial carcinoma and hyperplasia. Int J Gynecol Cancer 2010;20(1):92–101. DOI: 10.1111/IGC.0b013e3181bbe933Mustafa A., Bozdag Z., Tepe N.B., Ozcan H.C. An unexpected reason for elevated human chorionic gonadotropin in a young woman. Cervical squamous carcinoma. Saudi Med J 2016;37(8):905–7. DOI: 10.15537/smj.2016.8.14529Konstantinopoulos P.A., Matulonis U.A. Current status and evolution of preclinical drug development models of epithelial ovarian cancer. Front Oncol 2013;3:296. DOI: 10.3389/fonc.2013.00296Wu W., Gao H., Li X. et al. β-hCG promotes epithelial ovarian cancer metastasis through ERK/MMP2 signaling pathway. Cell Cycle 2019;18(1):46–59. DOI: 10.1080/15384101.2018.1558869Li J., Yin M., Song W. et al. B subunit of human chorionic gonadotropin promotes tumor invasion and predicts poor prognosis of early-stage colorectal cancer. Cell Physiol Biochem 2018;45(1):237–49. DOI: 10.1159/000486770.Guo X., Liu G., Schauer I.G. et al. Overexpression of the β subunit of human chorionic gonadotropin promotes the transformation of human ovarian epithelial cells and ovarian tumorigenesis. Am J Pathol 2011;179(3):1385–93. DOI: 10.1016/j.ajpath.2011.05.018Liu N., Peng S.M., Zhan G.X. et al. Human chorionic gonadotropin β regulates epithelial-mesenchymal transition and metastasis in human ovarian cancer. Oncol Rep 2017;38(3):1464–72. DOI: 10.3892/or.2017.5818Chernyshova A.L., Kolomiets L.A., Sinilkin I.G. et al. Optimization of approaches to choosing the scope of surgical treatment in patients with cervical cancer (the role of sentinel lymph node research). Voprosy onkologii = Oncology Issues 2016;62(6):807–11. (In Russ.).Чернышова А.Л., Коломиец Л.А., Синилкин И.Г. и др. Оптимизация подходов к выбору объема хирургического лечения у больных раком шейки матки (роль исследования сторожевых лимфоузлов). Вопросы онкологии 2016;62(6):807–11.Li Z., Li C., Du L. et al. Human chorionic gonadotropin β induces migration and invasion via activating ERK1/2 and MMP-2 in human prostate cancer DU145 cells. PLoS One 2013;8(2):e54592. DOI: 10.1371/journal.pone.0054592Wu Z., Wang T., Fang M. et al. MFAP5 promotes tumor progression and bone metastasis by regulating ERK/MMP signaling pathways in breast cancer. Biochem Biophys Res Commun 2018;498(3):495–501. DOI: 10.1016/j.bbrc.2018.03.007Guan H., Guo Z., Liang W. et al. Trop2 enhances invasion of thyroid cancer by inducing MMP2 through ERK and JNK pathways. BMC Cancer 2017;17(1):486. DOI: 10.1186/s12885-017-3475-2Qin H., Liu X., Li F. et al. PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling. Cancer Lett 2017;409:30–41. DOI: 10.1016/j.canlet.2017.08.019Wang J.L., Yang M.Y., Xiao S. et al. Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling. J Exp Clin Cancer Res 2018;37(1):45. DOI: 10.1186/s13046-018-0720-8Jung H.Y., Fattet L., Yang J. Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis. Clin Cancer Res 2015;21(5):962–8. DOI: 10.1158/1078-0432.CCR-13-3173Peixoto P., Etcheverry A., Aubry M. et al. EMT is associated with an epigenetic signature of ECM remodeling genes. Cell Death Dis 2019;10(3):205. DOI: 10.1038/s41419-019-1397-4Helmo F.R., Lopes A.M.M., Carneiro A.C.D.M. et al. Angiogenic and antiangiogenic factors in preeclampsia. Pathol Res Pract 2018;214(1):7–14. DOI: 10.1016/j.prp.2017.10.021Al Darwish F.M., Meijerink L., Coolen B.F. et al. From Molecules to imaging: assessment of placental hypoxia biomarkers in placental insufficiency syndromes. Cells 2023;12(16):2080. DOI: 10.3390/cells12162080Bashmakova N.V., Tsyv’ian P.B., Chistiakova G.N. et al. Angiogenic growth factors and the pathogenesis of preeclampsia. Rossiyskiy vestnik akushera-ginekologa = Russian Bulletin of Obstetrician-Gynecologist 2017;17(5):7–12. (In Russ.). DOI: 10.17116/rosakush20171757-12Башмакова Н.В., Цывьян П.Б., Чистякова Г.Н. и др. Ангиогенные ростовые факторы и патогенез преэклампсии. Российский вестник акушера-гинеколога 2017;17(5):7–12. DOI: 10.17116/rosakush20171757-12Sandvik M.K., Leirgul E., Nygård O. et al. Preeclampsia in healthy women and endothelial dysfunction 10 years later. Am J Obstet Gynecol 2013;209(6):569.e1–10. DOI: 10.1016/j.ajog.2013.07.024Gaugler-Senden I.P.M., Tamsma J.T., van der Bent C. et al. Angiogenic factors in women ten years after severe very early onset preeclampsia. PLoS One 2012;7(8):e43637. DOI: 10.1371/journal.pone.0043637Behrens I., Basit S., Jensen A. et al. Hypertensive disorders of pregnancy and subsequent risk of solid cancer – a nationwide cohort study. Int J Cancer 2016;139(1):58–64. DOI: 10.1002/ijc.30065Navarro V.M. Interactions between kisspeptins and neurokinin B. Adv Exp Med Biol 2013;784:325347. DOI: 10.1007/978-1-4614-6199-9_15/FIGURES/00155Wang T., Chen S., Wang S. et al. Targeting neurokinin-3 receptor: a novel anti-angiogenesis strategy for cancer treatment. Oncotarget 2017;8(25):40713. DOI: 10.18632/oncotarget.17250Xiang H., Toyoshima Y., Shen W. et al. IFN-α/β-mediated NK2R expression is related to the malignancy of colon cancer cells. Cancer Sci 2022;113(8):2513–25. DOI: 10.1111/cas.15397Fang W., Fu C., Chen X. et al. Neurokinin-2 receptor polymorphism predicts lymph node metastasis in colorectal cancer patients. Oncol Lett 2015;9(5):2003–6. DOI: 10.3892/ol.2015.3016Zhang X.W., Li L., Hu W.Q. et al. Neurokinin-1 receptor promotes nonsmall cell lung cancer progression through transactivation of EGFR. Cell Death Dis 2022;13(1):41. DOI: 10.1038/s41419-021-04485-yLee E.D. Endoplasmic reticulum aminopeptidase 2, a common immunological link to adverse pregnancy outcomes and cancer clearance? Placenta 2017;56:40–3. DOI: 10.1016/j.placenta.2017.03.012Tai W., Chen Z., Cheng K. Expression profile and functional activity of peptide transporters in prostate cancer cells. Mol Pharm 2013;10(2):477–87. DOI: 10.1021/mp300364kFarhadi S.A., Hudalla G.A. Engineering galectin–glycan interactions for immunotherapy and immunomodulation. Exp Biol Med 2016;241(10):1074–83. DOI: 10.1177/1535370216650055Huang Y., Wang H.-C., Zhao J. et al. Immunosuppressive roles of galectin-1 in the tumor microenvironment. Biomolecules 2021;11(10):1398. DOI: 10.3390/biom11101398Gordon-Alonso M., Bruger A.M., van der Bruggen P. Extracellular galectins as controllers of cytokines in hematological cancer. Blood 2018;132(5):484–91. DOI: 10.1182/blood-2018-04-846014Gordon-Alonso M., Hirsch T., Wildmann C., van der Bruggen P. Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration. Nat Commun 2017;8(1):793. DOI: 10.1038/s41467-017-00925-6